- This event has passed.
Bioscience Panel – Hosted by Connecticut Innovations
September 10 @ 9:00 am - 10:30 am
The discussion, moderated by Josh Geballe, Managing Director of Yale Ventures, will include insights from remarkable leaders from New Haven-based bioscience companies that have successfully exited CI’s portfolio.
The panelists include:
Dr. Vlad Coric, Biohaven: Dr. Vlad Coric is the CEO of Biohaven, a pharmaceutical company focused on creating groundbreaking treatments for neurological diseases, including rare disorders. Vlad led Biohaven’s landmark FDA approvals for its migraine drugs and spearheaded the acquisition of Biohaven’s CGRP portfolio by Pfizer in 2017.
Kevin Rocco, Biorez: Kevin Rocco served as the CEO and founder of Biorez, a medical device company developing advanced scaffold technologies for soft tissue repair, prior to its acquisition by ConMed in 2022. Kevin is an experienced entrepreneur and expert in tissue engineering, raising $12M in various fundings for Biorez.
Tim Shannon, Arvinas: Tim Shannon and Craig Crews co-founded Arvinas, a biopharmaceutical company developing protein degradation therapeutics to treat various diseases, which went public in 2018. Currently, Tim serves as General Partner of Canaan, a venture capital firm investing in visionaries with transformative ideas.
Josh Geballe, Yale Ventures: Josh Geballe is the managing director of Yale Ventures, where he supports programs for students, faculty, and the broader New Haven community, encouraging the launch of new startups based on Yale research and providing training in entrepreneurship and innovation.